Tonix Pharmaceuticals (NASDAQ:TNXP) Now Covered by StockNews.com

StockNews.com started coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a report released on Tuesday. The firm set a “sell” rating on the stock.

Separately, Alliance Global Partners upped their price target on Tonix Pharmaceuticals from $6.00 to $11.00 and gave the stock a “buy” rating in a research note on Monday, July 22nd.

Tonix Pharmaceuticals Stock Performance

NASDAQ TNXP opened at $0.14 on Tuesday. The company has a 50-day moving average of $0.17 and a 200-day moving average of $1.74. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.15 and a quick ratio of 0.72. Tonix Pharmaceuticals has a 12 month low of $0.12 and a 12 month high of $22.14. The company has a market cap of $19.46 million, a P/E ratio of 0.00 and a beta of 2.06.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its quarterly earnings results on Friday, August 16th. The company reported ($19.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($9.91) by ($9.37). The company had revenue of $2.21 million for the quarter, compared to analysts’ expectations of $3.50 million. Tonix Pharmaceuticals had a negative return on equity of 158.27% and a negative net margin of 1,196.11%. As a group, equities analysts predict that Tonix Pharmaceuticals will post -18 earnings per share for the current year.

Hedge Funds Weigh In On Tonix Pharmaceuticals

A hedge fund recently raised its stake in Tonix Pharmaceuticals stock. Acadian Asset Management LLC boosted its position in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 260.6% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 335,373 shares of the company’s stock after purchasing an additional 242,358 shares during the period. Acadian Asset Management LLC owned approximately 0.40% of Tonix Pharmaceuticals worth $61,000 at the end of the most recent reporting period. 82.26% of the stock is currently owned by institutional investors.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.